BioCardia freezes primary outcomes data in Phase 3 CardiAMP HF trial; results at ACC 2025

BioCardia, Inc.

Source data verified and data frozen for 115 patients in double-blind, placebo-controlled Phase 3 trial for ischemic HFrEF.
Data transferred to Statistical Data Analysis Center core laboratory for analysis.
Results scheduled for Late-Breaking Clinical Trials symposium at ACC 2025 on March 30, 2025 in Chicago.
CEO states the study is intended to support safety and effectiveness for US and Japan approvals and Helix delivery system approval.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.